Finland· FI-REL-REL50665
Besremi
A ropeginterferon alfa-2b product containing ropeginterferon alfa-2b, registered in Finland by Aop Orphan Pharmaceuticals GmbH. The same ATC class is registered in 12 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Ropeginterferon alfa-2b is registered in 12 of 19 countries.
Countries holding a registration under ATC L03AB15 (ropeginterferon alfa-2b), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 8 of them publish a price we can compare per daily dose
Ropeginterferon alfa-2b · ATC L03AB15
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Fimea (Finland)- Active substance
- Ropeginterferon alfa-2b
- Manufacturer
- Aop Orphan Pharmaceuticals GmbH
- Country
- Finland (FI)
- ATC code
- L03AB15
- ATC class
- Ropeginterferon alfa-2b
- Defined daily dose
- 18 mcg, P
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ropeginterferon alfa-2b in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesBESREMiPharmaEssentia USA
- NorwayBesremiAOP Orphan Pharmaceuticals AG
- CzechiaBESREMIAOP Orphan Pharmaceuticals GmbH, Wien
- NetherlandsBesremi 250 microgram/0,5 ml oplossing voor injectie in een voorgevulde penAOP Orphan Pharmaceuticals AG
- IrelandBesremi 250 micogram/0.5 ml Solution for injection in pre-filled penAop Orphan Pharmaceuticals GmbH
- SwitzerlandBesremi
- BelgiumBesremi 250 µg/0.5 mlAOP Orphan Pharmaceuticals
- IcelandBesremiAOP Orphan Pharmaceuticals GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Besremi
- Liechtenstein · Besremi
- Norway · Besremi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bb1c1854-b94a-4448-814a-17eb9ac8943d GET /v1/drugs/bb1c1854-b94a-4448-814a-17eb9ac8943d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "injektioneste, liuos, esitäytetty kynä",
"route": "Ihon alle",
"ddd_unit": null,
"strength": "250 mikrog / 0.5 ml",
"atc_label": "ropeginterferoni alfa-2b",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/18/1352/001, 003",
"fimea_rel_id": "REL50665",
"authorised_at": "2019-02-15"
}See everything about ropeginterferon alfa-2b.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.